ZBIO Zenas BioPharma, Inc.

NASDAQ
$26.95

Zenas BioPharma, Inc. (ZBIO) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $1.23 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.3% since its last earnings release on August 13, 2026.

Zenas BioPharma Missed Consensus Estimates
Thursday, August 13, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 7:00 AM ET
Earnings Whisper
-
vs ($1.23)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $31.74

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Zenas BioPharma, Inc.

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.